GIVE YOUR PATIENTS
THE CONFIDENCE TO DO WHAT THEY LOVE,
WHEREVER THEY ARE.
VYEPTI® (eptinezumab) is an anti-CGRP monoclonal antibody indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.1 VYPETI is administered via one 30-minute intravenous infusion, every 12 weeks.1 Explore the questions below to find out more about how VYEPTI could help your patients.
?>
Who are the
FIND OUT MORE
?>
What are the
FIND OUT MORE
?>
How does
FIND OUT MORE
?>
What is the
FIND OUT MORE
?>
How soon after
FIND OUT MORE
?>
When in the
FIND OUT MORE
?>
How does
FIND OUT MORE
?>
What needs to be
FIND OUT MORE
Who are the
right patients
or VYEPTI?
FIND OUT MORE
What are the
benefits of
VYEPTI IV?
FIND OUT MORE
How does
VYEPTI work?
FIND OUT MORE
What is the
clinical evidence
for VYEPTI?
FIND OUT MORE
How soon after
infusion does VYEPTI
start working?
FIND OUT MORE
When in the
treatment pathway
should VYEPTI be used?
FIND OUT MORE
How does
VYEPTI impact
quality of life?
FIND OUT MORE
What needs to be
considered when
administering VYEPTI IV?
FIND OUT MORE
CONTACT US
LET’S
CONNECT
Schedule a meeting about VYEPTI with your local Lundbeck representative
HERE
TO HELP
Contact us with any general or
product-related queries
STAY
IN TOUCH
To receive information and
updates about VYEPTI,
sign up for promotional
communications from Lundbeck
